Becton, Dickinson and Company
BDX.SW
Swiss Exchange245.48
CHF
- -
- -
Becton, Dickinson and Company
BDX.SW
(Swiss Exchange)
Recent
price
245.48
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Becton, Dickinson and Company (BD) is a leading global medical technology company specializing in the development, manufacture, and sale of medical devices, instrument systems, and reagents. Its core product portfolio includes prefillable syringes and injectable drug delivery systems; safety and needle shielding systems; infusion therapy products such as the BD Alaris Infusion System; diagnostic systems including the BD Phoenix automated microbiology system and BD Vacutainer urinalysis products; and surgical and interventional instruments including atherectomy and thrombectomy devices. BD also provides analytical and consulting services related to drug delivery system development, lifecycle management, and regulatory compliance. The company operates across healthcare institutions, clinical laboratories, life science research, and pharmaceutical industries, with a presence spanning North America, Europe, Asia, and other global markets. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD maintains a broad manufacturing and service footprint globally. In recent strategic developments, BD announced a plan to spin off its life sciences and diagnostics businesses to sharpen its focus on medical technology, aiming to create a "New BD" focused on healthcare provider and patient end-markets. This restructuring expects the New BD to generate approximately $17.8 billion in fiscal 2024 revenue with a market opportunity exceeding $70 billion. In 2024, BD completed the acquisition of Edwards Lifesciences' critical care unit for $4.2 billion, expanding its portfolio in critical care technologies. BD is also actively advancing its pipeline under the "BD 2025" growth plan, targeting the launch of over 100 new products by the end of fiscal 2025 to accelerate organic revenue growth. Notably, BD continues to introduce innovative solutions such as the Rotarex catheter system for peripheral artery disease and the first FDA-cleared rapid point-of-care COVID-19 test. These initiatives reflect BD’s commitment to innovation and market expansion in medical technology while divesting non-core segments to enhance operational focus and growth.